Invenra Highlights Exelixis’ Phase 1 Trial of XB010 for Advanced Tumors

In Madison, Wisconsin, on August 7, 2024, Invenra's collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), announced the start of the dose-escalation phase of a first-in-human phase 1 clinical trial for the drug XB010. This trial involves patients with locally advanced or metastatic solid tumors.

XB010 is an antibody-drug conjugate (ADC) that combines a monomethyl auristatin E payload with a monoclonal antibody targeting the tumor antigen 5T4. This innovative ADC is the first product created through Exelixis' biotherapeutics collaboration network. The drug was developed using Catalent's SMARTag site-specific bioconjugation technology, and the 5T4-targeting monoclonal antibody was discovered in collaboration with Invenra.

Exelixis has also announced that the dose-escalation phase of their global, open-label phase 1 study will test XB010 as both a standalone treatment and in combination with pembrolizumab. The goal is to collect data that will inform the next stage, which involves cohort expansion. The expansion cohorts will provide further insights into the drug’s tolerability and its activity as a monotherapy and in combination treatments for specific types of tumors.

The ongoing research and clinical trials are a significant step forward in the fight against advanced and metastatic solid tumors, potentially offering new therapeutic options for patients facing these challenging conditions.